Myriad Genetics INC Form 4 insider transactions
NASDAQ
Myriad Genetics Inc. Director Mark Steven Davis was granted 24,148 restricted stock units of common stock on June 5, 2025, increasing his direct beneficial ownership to 46,964 shares.
NASDAQ
Myriad Genetics Inc. Director Lee Nisley Newcomer reported the acquisition of 49,796 shares of common stock through a restricted stock unit grant on June 5, 2025, increasing her total beneficial ownership to 132,141 shares.
NASDAQ
Myriad Genetics Inc. Director Colleen F. Reitan was granted 49,796 restricted stock units, increasing her beneficial ownership to 92,329 shares.
NASDAQ
Myriad Genetics Inc. Director Rashmi Kumar was granted 49,796 restricted stock units, increasing her beneficial ownership in the company to 127,188 shares.
NASDAQ
Myriad Genetics, Inc. Director Daniel Skovronsky has acquired 49,796 shares of common stock in the form of restricted stock units, as disclosed in a recent SEC Form 4 filing.
NASDAQ
Myriad Genetics, Inc. President and CEO, Samraat S. Raha, acquired 1,498 shares of common stock on May 31, 2025, through the company's Employee Stock Purchase Plan.
NASDAQ
Brian J. Donnelly, Chief Commercial Officer of Myriad Genetics, reports the acquisition of time-based and performance-based restricted stock units.
NASDAQ
Mark Verratti, Chief Operating Officer of Myriad Genetics, was granted performance-based restricted stock units (PSUs) on April 30, 2025, tied to the company's stock price performance.
NASDAQ
Myriad Genetics CEO Samraat S. Raha was granted 141,050 performance-based restricted stock units (PSUs) tied to the company's stock price performance.
NASDAQ
Paul Diaz, former President and CEO of Myriad Genetics, files a Form 4 to report his departure from the company, effective April 30, 2025.
NASDAQ
Dale Muzzey, Chief Scientific Officer of Myriad Genetics, sold shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports a transaction involving the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports disposing of shares to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Form 4: Myriad Genetics Chief Accounting Officer Natalie Munk Reports Stock Disposals for Tax Obligations
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the disposal of shares to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Form 4: Myriad Genetics Executive Kevin Richard Haas Reports Stock Disposals to Cover Tax Obligations
Kevin Richard Haas, Chief Technology Officer of Myriad Genetics, reported the disposal of common stock to cover tax withholding obligations related to vesting restricted stock units.
NASDAQ
Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Chief Commercial Officer Mark Verratti of Myriad Genetics reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Paul J. Diaz, President and CEO of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports acquisition and disposal of company stock related to restricted stock units.
NASDAQ
Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports acquisition and disposal of common stock and restricted stock units.
NASDAQ
Shereen Solaiman, Chief People Officer of Myriad Genetics, reports acquisition of restricted stock units and disposition of shares to cover tax obligations.
NASDAQ
Chief Technology Officer Kevin Richard Haas of Myriad Genetics Inc. reports acquisition and disposal of common stock due to vesting of restricted stock units and tax withholding.
NASDAQ
Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reports acquisition and disposal of company stock related to restricted stock units.
NASDAQ
Jennifer Lynne Fox, Chief Legal Officer of Myriad Genetics, reports the acquisition of 63,145 shares of common stock and the disposal of 124,916 shares.
NASDAQ
Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports acquisition and disposal of company stock related to restricted stock units and tax obligations.
NASDAQ
Scott Leffler, CFO of Myriad Genetics, reports acquisition of restricted stock units and disposition of shares to cover tax obligations.
NASDAQ
Chief Operating Officer of Myriad Genetics, Samraat S. Raha, reports acquisition and disposal of company stock, including restricted stock units and shares withheld for tax obligations.
NASDAQ
Paul Diaz, CEO of Myriad Genetics, disposed of shares to cover tax obligations related to vesting restricted stock units.
NASDAQ
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports the acquisition of 3,316 shares of common stock on February 7, 2025, related to performance-based restricted stock units.